



Organ on Chip in Development (ORCHID)

EU – H2020 project grant agreement no 766884 (AMD-766884-3)

Website: www.H2020-ORCHID.eu

Deliverable Number	5.8
Deliverable Title	Organ-on-chip as next drug discovery route
Short Title	OoC_drug_discovery
Lead beneficiary	5-IMEC
Del. Date (Annex 1)	M24
Achieved Date	29/09/2019
Nature	Report
Dissemination Level	PU
Document Filename	D58-OoC_drug_discovery-M24-PU-v1.0.pdf

Date	Authors/Reviewers	Remarks	Version
07/08/2019	Thomassen	Provided format	0.0
26/09/2019	Braeken, Eberle		0.1
27/09/2019	van den Eijnden-van Raaij		0.2
29/09/2019	Braeken		0.3
30/09/2019	van den Eijnden-van Raaij, Thomassen		0.4
		Final Version submitted to EC	1.0

Contents

Executive Summary.....	3
Introduction and current status.....	3
Moving forward	4
References	6

Executive Summary

Organ-on-chip (OoC) is a promising technology that might have a potential strong impact on drug discovery. This document discusses opportunities for OoC systems in drug discovery, today and in the future. These are based on opinions and discussions from experts at the ORCHID workshops, and literature examples^{1,2}. Finally, we discuss how the European Organ-on-Chip Society (EUROoCS) can play a role in facilitating adoption of OoC in this scheme, and what the expected impact in the future can be.

Introduction and current status

Organ-on-chip (OoC) is a promising new technology with a potential large impact on how we will evaluate and develop drugs in the future. In the ORCHID project OoC technology related opportunities and challenges were examined from all possible perspectives, i.e. societal, economical, ethical, regulatory, etc. During several workshops we consulted experts and stakeholders in the field and together with them we defined key areas of use for OoC technology: prediction of drug efficacy & toxicity, understanding human disease and the route towards personalized medicine². Figure 1 demonstrates the drug discovery process and the opportunities for OoC technology as discussed by a report of t⁴ – the transatlantic think tank for toxicology (Beilmann et al. 2019).




Fig. 1. The drug discovery process and opportunities for OoC systems. Reproduced from *Beilmann et al. 2019*.

¹ [Organ-on-Chip in Development: Toward a roadmap for organs-on-chip](#)

² [Building blocks for a European Organ-on-Chip roadmap](#)

In the short term it is likely that especially drug safety or toxicology might represent a *beach head market* for qualification of OoC devices and technology. Drug safety/ adverse effects are typically performed in the pre-clinical stage of drug development. In this stage, drug candidates already selected through the initial discovery process (lead optimization) are being validated before they move into the clinical phase (testing on human individuals). Novel methods, such as OoC devices can then be used in parallel with existing, animal- or non-animal-based methods (Valentin et al. 2010; Hardwick et al. 2017). Drug safety always needs to be assessed in the right context, i.e. using the correct set of reference compounds. A good example of introduction of novel methods and subsequent international harmonization in the drug safety field is the CiPA initiative³ (Servick 2016). This process could be used as a blueprint for the introduction of new technology adoption (such as OoC) in the drug discovery development, specifically for safety.

At this moment, for OoC devices there is a need for evidence-based data and qualified models. OoC methods can be introduced in two steps: (1) by producing missing, i.e. complementary data next to established methods before (2) replacing some of the established methods later on. This allows for a gradual transition that would put pharma & regulators more at ease and creates the necessary evidence where OoC methods could lead to reduction or even replacement of animal testing. There are several key academic efforts available today that take the necessary leap forward by assessing the OoC device/system in the relevant context of use and comparing it to ground root data sets, such as animal based and *in vivo* human data (Maass et al. 2017; Prantil-Baun et al. 2018; Maass et al. 2019; Foster et al. 2019; Ewart et al. 2018). Quick wins can be identified first – e.g. a complementary device or method to an existing approach. This allows for quicker adoption compared to long developments.

Next steps for qualification include performing intra- and inter-laboratory assays to assess reproducibility and accuracy and assess stability and robustness of the device/method. The CiPA initiative has been using this qualification route as well and is close to setting a novel international guideline to update ICH S7B and E14 (Millard et al. 2018). Independent testing centres such as the NCATS in the USA act as a third party ensuring an independent characterization and are key to this process for OoC⁴.

Moving forward

The existing OoC community that was built partially by EUROoCS and ORCHID partners is an extremely valuable ecosystem. EUROoCS is a growing community that already has 167 members from academia, industry, regulatory agencies, patient associations and other organizations in more than 20 countries worldwide. This community should reach out globally and initiate dialogues with all stakeholders to define the OoC roadmap in Europe. The EUROoCS society can take the task to set up working groups around a specific topic, such as safety screening, for example, to stimulate the right interactions and enable the road to international harmonization. Other use cases can follow that model.

³ <https://cipaproject.org/>

⁴ <https://ncats.nih.gov/tissuechip/projects/centers>

Currently, with the support and in the context of EUROoCS a European OoC Infrastructure is being designed that will bridge the gap between Developers and End User applications and support widespread implementation and acceptance of the OoC models: from experimental model to standard product. This infrastructure will select and qualify models based on criteria defined and established jointly by Developer and End User stakeholders that include the European OoC Society (EUROoCS), the Netherlands Organ-on-Chip Consortium (hDMT), regulatory agencies such as the European Medicines Agency (EMA) and the Food and Drug Administration (FDA; USA) and representatives of pharma. Models that comply with initial requirements will be taken forward to in depth testing and qualification leading to fully characterized models with guidelines and standard operating procedures on use and applications. All results will be available in a database based on FAIR guidelines, and will help end users to choose the right model for their applications. In addition, complex *in silico* modelling (PK/PD modelling) based on clinical data available through the regulatory agencies and pharma will support *in vitro* to *in vivo* translation.

EUROoCS can also act as a communication channel to promote specific topics, organize theme-based meetings and leverage the website to broaden the OoC network and share access to data⁵. The society should also help to develop training programs and stimulate communication and dissemination (e.g. through a journal). Policy makers can take this opportunity to actively help promote and even guide this process. In Europe, there are several calls in work programmes available today to promote research on OoC, but there is also a need for logistical and communication actions.

In addition to safety screening purposes, these OoC systems can also be used for efficacy testing. There are examples of OoC systems being used for PD/PK modelling (Prantil-Baun et al. 2018). For the development of new disease models, organ-level functions are required that recapitulate key phenotypic features of human disease in a cell or tissue. Animal models have been used to try model this complexity, but with limited success. The use of the relative unlimited source of cells with defined phenotypes and genotypes, such as induced pluripotent stem cells, is a promising path forward. These can then be differentiated into the desired somatic cells for the target organ. Introducing further complexity by culturing in three dimensions and adding flow, chemical gradients and mechanical strain to the cell/tissues would display more physiologically relevant attributes. The use of patient cell material opens the avenue to true personalized medicine approaches, in which a 'patient-on-chip' can be developed, that might replace or complement Phase I and Phase 2 clinical trials.

⁵ <https://euroocs.eu/>

References

- Beilmann, Mario, Harrie Boonen, Andreas Czich, Gordon Dear, Philip Hewitt, Tomas Mow, Peter Newham, et al. 2019. "Optimizing Drug Discovery by Investigative Toxicology: Current and Future Trends." In *Altex*. <https://doi.org/10.14573/altex.1808181>.
- Ewart, Lorna, Eva-Maria Dehne, Kristin Fabre, Susan Gibbs, James Hickman, Ellinor Hornberg, Magnus Ingelman-Sundberg, et al. 2018. "Application of Microphysiological Systems to Enhance Safety Assessment in Drug Discovery." *Annual Review of Pharmacology and Toxicology*. <https://doi.org/10.1146/annurev-pharmtox-010617-052722>.
- Foster, Alison J., Bhavik Chouhan, Sophie L. Regan, Helen Rollison, Sara Amberntsson, Linda C. Andersson, Abhishek Srivastava, et al. 2019. "Integrated in Vitro Models for Hepatic Safety and Metabolism: Evaluation of a Human Liver-Chip and Liver Spheroid." *Archives of Toxicology*. <https://doi.org/10.1007/s00204-019-02427-4>.
- Hardwick, R. N., C. Viergever, A. E. Chen, and D. G. Nguyen. 2017. "3D Bioengineered Tissues: From Advancements in in Vitro Safety to New Horizons in Disease Modeling." *Clinical Pharmacology and Therapeutics*. <https://doi.org/10.1002/cpt.569>.
- Maass, Christian, Nathan B. Sorensen, Jonathan Himmelfarb, Edward J. Kelly, Cynthia L. Stokes, and Murat Cirit. 2019. "Translational Assessment of Drug-Induced Proximal Tubule Injury Using a Kidney Microphysiological System." *CPT: Pharmacometrics and Systems Pharmacology*. <https://doi.org/10.1002/psp4.12400>.
- Maass, Christian, Cynthia L. Stokes, Linda G. Griffith, and Murat Cirit. 2017. "Multi-Functional Scaling Methodology for Translational Pharmacokinetic and Pharmacodynamic Applications Using Integrated Microphysiological Systems (MPS)." *Integrative Biology (United Kingdom)*. <https://doi.org/10.1039/c6ib00243a>.
- Millard, Daniel, Qianyu Dang, Hong Shi, Xiaou Zhang, Chris Strock, Udo Kraushaar, Haoyu Zeng, et al. 2018. "Cross-Site Reliability of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Based Safety Assays Using Microelectrode Arrays: Results from a Blinded CiPA Pilot Study." *Toxicological Sciences* 164 (2): 550–62. <https://doi.org/10.1093/toxsci/kfy110>.
- Prantil-Baun, Rachele, Richard Novak, Debarun Das, Mahadevabharath R. Somayaji, Andrzej Przekwas, and Donald E. Ingber. 2018. "Physiologically Based Pharmacokinetic and Pharmacodynamic Analysis Enabled by Microfluidically Linked Organs-on-Chips." *Annual Review of Pharmacology and Toxicology*. <https://doi.org/10.1146/annurev-pharmtox-010716-104748>.
- Servick, K. 2016. "A Painstaking Overhaul for Cardiac Safety Testing." *Science*. <https://doi.org/10.1126/science.353.6303.976>.
- Valentin, Jean Pierre, Chris Pollard, Pierre Lainée, and Tim Hammond. 2010. "Value of Non-Clinical Cardiac Repolarization Assays in Supporting the Discovery and Development of Safer Medicines." *British Journal of Pharmacology*. <https://doi.org/10.1111/j.1476-5381.2009.00530.x>.